info:eu-repo/semantics/article
Disaccharides obtained from carrageenans as potential antitumor agents
Fecha
2019-12Registro en:
Calvo, Gustavo Hernán; Cosenza, Vanina; Saenz, Daniel Alberto; Navarro, Diego Alberto; Stortz, Carlos Arturo; et al.; Disaccharides obtained from carrageenans as potential antitumor agents; Nature Publishing Group; Scientific Reports; 9; 1; 12-2019; 1-13
2045-2322
CONICET Digital
CONICET
Autor
Calvo, Gustavo Hernán
Cosenza, Vanina
Saenz, Daniel Alberto
Navarro, Diego Alberto
Stortz, Carlos Arturo
Céspedes, Mariela Anahí
Mamone, Leandro Ariel
Casas, Adriana Gabriela
Di Venosa, Gabriela Mariana
Resumen
Carrageenans are sulfated galactans found in certain red seaweeds with proven biological activities. In this work, we have prepared purified native and degraded κ-, ι-; and λ-carrageenans, including the disaccharides (carrabioses) and disaccharide-alditols (carrabiitols) from seaweed extracts as potential antitumor compounds and identified the active principle of the cytotoxic and potential antitumor properties of these compounds. Both κ and ι-carrageenan, as well as carrageenan oligosaccharides showed cytotoxic effect over LM2 tumor cells. Characterized disaccharides (carrabioses) and the reduced product carrabiitols, were also tested. Only carrabioses were cytotoxic, and among them, κ-carrabiose was the most effective, showing high cytotoxic properties, killing the cells through an apoptotic pathway. In addition, the cells surviving treatment with κ-carrabiose, showed a decreased metastatic ability in vitro, together with a decreased cell-cell and cell-matrix interactions, thus suggesting possible antitumor potential. Overall, our results indicate that most cytotoxic compounds derived from carrageenans have lower molecular weights and sulfate content. Potential applications of the results emerging from the present work include the use of disaccharide units such as carrabioses coupled to antineoplasics in order to improve its cytotoxicity and antimetastatic properties, and the use of ι-carrageenan as adjuvant or carrier in anticancer treatments.